Earth Life Sciences Inc.
CLTS · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.00 | 0.53 | 0.07 |
| FCF Yield | -0.50% | -0.83% | -0.00% | 0.00% |
| EV / EBITDA | -2.21 | -3.19 | -45.61 | -6.92 |
| Quality | ||||
| ROIC | -35.95% | -1,470.66% | 94.41% | 174.30% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.01 | 0.02 | 0.00 | – |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 65.04% | -132,111.73% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.19 | -0.18 | -0.61 | -0.07 |
| Interest Coverage | -72.60 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -42,430.13 | -187,547.43 |